The drug is indicated for adults with mild cognitive impairment or mild dementia, who are non-carriers or heterozygotes of apolipoprotein E ε4 (ApoE ε4) with confirmed amyloid pathology. The post Leqembi approved in Australia to treat early Alzheimer’s appeared first on Pharmaceutical Business review.